DevEx Resources Limited (ASX: DEV) is leaning hard into the Northern Territory uranium thesis with a 2025 program that moves from mapping to gravity-constrained drilling across Nabarlek’s Big Radon and KP prospects (Figure 1)—two kilometre-scale radon anomalies now tied to fault architecture by new ground gravity. Heritage clearances are being finalised and the NT Government has tipped in $160k to co-fund the maiden holes, a tidy endorsement at this stage.

Yandal Resources Ltd (ASX: YRL) has confirmed a new gold discovery at the Arrakis Prospect within the Caladan target area of the Ironstone Well–Barwidgee Project — a major milestone that de-risks exploration and advances the project (Figure 1). With 54m @ 1.2g/t Au from fresh rock, including 8m @ 4.7g/t Au, the result highlights scale and continuity over more than 2.2km of strike.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has taken a major step toward establishing a commercial presence in the Australian and New Zealand markets. The company has entered into an exclusive licensing agreement with global pharmaceutical manufacturer Sakar Healthcare Limited (NSE: SAKAR, BSE: 538377) (Figure 1) to launch five oncology medicines across the region.

AuMEGA Metals Limited (ASX: AAM) has reported a standout result from its July airborne time-domain EM survey over Cape Ray: the work both maps known mineralisation at Central Zone and—critically—defines a large, previously untested conductor just 500 m to the southeast that mirrors Central Zone’s geophysical signature. With a fully funded drilling program slated for Q4 2025, the discovery pipeline at Cape Ray continues to expand.

Terra Critical Minerals Limited (ASX: T92) has confirmed a new high-grade silver discovery at the Silent Grove Prospect within its 100%-owned Mole River Project in New South Wales (Figure 1). This update represents an important step forward in unlocking the polymetallic potential of the Mole Granite district, an area already known for tin, tungsten, and silver-rich systems.

DY6 Metals Ltd (ASX: DY6) has delivered a practical operational update across its Malawian projects (Figure 1), completing follow-up surface sampling at Tundulu and commencing a new grid-based program at Machinga. The work targets high-value mineralisation in gallium (Ga), rare earth elements (REEs), niobium (Nb) and phosphate, with assays in preparation for SGS Randfontein.

Kaiser Reef Limited (ASX: KAU) has marked its first full quarter since acquiring the Henty Gold Mine, with reconciled production reported for 1 July–30 September 2025. Alongside the steadying of Henty as the core asset, the quarter featured renewed activity at Maldon and a strategic transition at A1, setting a clearer operational footing across the portfolio.

When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question – what just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation.

Key Investment Trends That has shaped Investor Opportunities ASX in 2025.

Thunderbird Resources Limited (ASX: THB) has executed a binding agreement to acquire 100% of the Springfield Gold Deposit in central NSW (Figure 1) — a project with historical shallow drilling, multiple thick, high-grade intercepts, and significant exploration upside. Alongside this acquisition, Thunderbird has secured $2.2M through a placement at $0.014/share, ensuring it is well-funded to accelerate its exploration programs.